Trastuzumab deruxtecan demonstrated a 34% reduction in the risk of death and a 13-month increase in overall survival compared with treatment of physician’s choice in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who received prior treatment with trastuzumab emtansine.
Ibrahim Aldoss, MD, discussed the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small…
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
